Long-term neprilysin gene transfer is associated with reduced levels of intracellular Abeta and behavioral improvement in APP transgenic mice
2008

Long-term neprilysin gene therapy improves behavior in Alzheimer's mice

Sample size: 24 publication Evidence: moderate

Author Information

Author(s): Spencer Brian, Marr Robert A, Rockenstein Edward, Crews Leslie, Adame Anthony, Potkar Rewati, Patrick Christina, Gage Fred H, Verma Inder M, Masliah Eliezer

Primary Institution: University of California San Diego

Hypothesis

Long-term neprilysin gene transfer will reduce intracellular Aβ levels and improve behavioral outcomes in APP transgenic mice.

Conclusion

Long-term neprilysin gene therapy improves behavioral performance and reduces neurodegenerative pathology by lowering intracellular Aβ levels.

Supporting Evidence

  • Neprilysin gene transfer reduced amyloid plaque load by 48% in the neocortex and 25% in the hippocampus.
  • Mice treated with neprilysin showed improved performance in the water maze test.
  • Long-term neprilysin expression was confirmed through immunocytochemical analysis.

Takeaway

Researchers gave a special treatment to mice with Alzheimer's that helped them think better and reduced harmful substances in their brains.

Methodology

The study involved injecting APP transgenic mice with lentiviral vectors expressing neprilysin and assessing behavioral performance and Aβ levels over six months.

Limitations

The long-term effects of high neprilysin expression levels remain unclear and may pose risks.

Participant Demographics

APP transgenic mice, aged 6 months at the start of the study.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1471-2202-9-109

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication